Quick Take: Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study
Anti-tumor necrosis factor (TNF) therapies are commonly used in the treatment of patients with moderate to severe Crohn’s disease. However, ...